696P is It Possible to Improve the Prognostic Ability of the IMDC Score? Validation of the Meet-URO Score in Metastatic Renal Cell Carcinoma (mrcc) Patients (pts) Receiving First-Line Nivolumab Plus Ipilimumab in the Italian Expanded Access Program (EAP)